The global dengue vaccines market is expected to expand at a robust CAGR of 11% during the forecast period and is projected to cross US$ 1.4 Bn by 2031. Rising prevalence of dengue across tropical and subtropical regions, increasing government support for immunization programs, and continued research into vaccines targeting all four dengue virus serotypes are supporting market development.

Dengue is a mosquito-borne viral disease caused by four closely related serotypes: DEN 1, DEN 2, DEN 3, and DEN 4. According to the supplied market data, nearly 390 million people are infected with dengue each year across 120 countries, particularly in Latin America, Southeast Asia, and Africa. The growing disease burden is encouraging pharmaceutical companies, research institutions, and governments to strengthen vaccine development and vaccination programs.

Potential Inverse Correlation Between Dengue and COVID-19

During the COVID-19 pandemic, research by institutions including Duke University, Oswaldo Cruz Foundation, University of Sao Paulo, and Federal University of Paraiba examined a potential relationship between dengue immunity and COVID-19 incidence. According to the supplied research findings, regions of Brazil with higher antibody levels against dengue recorded lower incidences of coronavirus infection and mortality.

Several million dengue cases were reported in Brazil between January 2019 and July 2020. These observations generated additional interest in understanding whether prior dengue immunization could influence susceptibility to COVID-19. However, such findings represent research observations and do not establish dengue vaccination as a proven preventive treatment for COVID-19.

The pandemic also highlighted the importance of vaccine safety communication. Companies in the dengue vaccines market have been emphasizing lessons from the 2016 Philippines dengue vaccine controversy to support greater awareness and informed vaccine adoption.

Companies Increase R&D to Develop Vaccines Against All Four Serotypes

Developing an effective dengue vaccine remains challenging because the virus exists in four antigenically distinct serotypes. An effective vaccine needs to provide broad and balanced protection across all four serotypes while addressing the complex immunopathology associated with dengue.

The lack of suitable animal models and reliable markers for protective immunity has further complicated vaccine development. Consequently, companies and research institutions are exploring multiple technological approaches, including live attenuated virus vaccines, subunit vaccines, and live chimeric virus vaccines.

The Butantan/Merck vaccine has received attention because of its approach involving three full genomes of the four dengue virus serotypes. Several other candidates are also progressing through different stages of research and clinical development.

Sequential Vaccination Gains Research Attention

Sequential vaccination and heterologous prime-boost approaches are being investigated as potential strategies for achieving stronger tetravalent protection. Research organizations such as the Singapore-MIT Alliance for Research and Technology (SMART) are examining approaches that could improve the safety and effectiveness of dengue vaccination.

Since suitable animal models remain limited, researchers are also using proof-of-concept studies in mice to investigate methods for inducing strong and broad immunity against dengue virus.

The market's projected 11% CAGR reflects increasing research activity, with companies drawing on experience from existing products such as Dengvaxia, which contains four variant dengue antigens.

Asia Pacific Creates Incremental Opportunities for Dengue Vaccine Development

Asia Pacific is expected to account for the highest revenue share of the global dengue vaccines market during the assessment period. High disease prevalence, increasing awareness, expanding immunization programs, and regulatory activity across dengue-endemic countries are creating opportunities for vaccine manufacturers.

Japan-based Takeda Pharmaceutical Company Limited has initiated regulatory submissions for its dengue vaccine candidate TAK-003 in the European Union and dengue-endemic countries including Brazil, Indonesia, and Mexico. Such developments are encouraging other market participants to pursue regulatory strategies and parallel assessments for vaccine candidates.

Companies are also focusing on vaccines intended for individuals between four and 60 years of age, creating opportunities across countries such as Malaysia, Thailand, and Singapore.

R&D Emerges as a Key Competitive Strategy

Research and development remains one of the most important strategies for companies seeking to strengthen their position in the dengue vaccines market. Continued innovation is aimed at improving vaccine acceptability, production efficiency, affordability, and protection against all four dengue virus serotypes.

The Developing Countries Vaccine Manufacturers Network (DCVMN) is also strengthening its role in vaccine development and manufacturing. Network members associated with dengue vaccine development are expanding production capabilities to address the burden of dengue and other infectious diseases in endemic regions.

Greater manufacturing capacity could be particularly important for countries where dengue represents a persistent public health challenge.

Access to Safe and Effective Vaccine Candidates Supports Endemic Countries

The World Health Organization has identified dengue as one of the major global health threats. Consequently, improving access to safe and effective vaccines remains an important objective for countries with high dengue incidence.

Panacea Biotec has announced the successful completion of a Phase I/II study of its tetravalent recombinant chimeric dengue vaccine candidate DengiAll. Such developments are encouraging companies to advance vaccine candidates capable of generating robust, balanced, and neutralizing antibody responses against all four dengue serotypes.

Countries including Colombia, Sri Lanka, and Argentina could benefit from greater access to effective dengue prevention strategies as vaccine development and commercialization progress.

Funding Programs Strengthen Indo-U.S. Vaccine Research

Government-backed funding and international collaborations are contributing to dengue vaccine research in India. The Department of Biotechnology in India has supported vaccine R&D through its Vaccine Action Program, while the Human Immunology Project Consortium (HIPC) Collaboration is supporting India-U.S. collaborative research on human immunophenotyping, infectious diseases, and vaccine development.

The International Centre for Genetic Engineering and Biotechnology (ICGEB), involving Sun Pharma, is also working on a recombinant EDIII-based subunit dengue vaccine candidate for injectable vaccine development.

Such initiatives are helping strengthen the research ecosystem for dengue and other infectious diseases while encouraging collaboration among pharmaceutical companies, research institutions, and government organizations.

Dengue Vaccines Market: Overview

Dengue is primarily prevalent in tropical and subtropical regions and can cause symptoms including severe headaches, nausea, rashes, bone pain, bleeding, and, in severe cases, death. The disease can persist for up to 10 days and requires timely medical attention.

According to the supplied data, the Americas recorded approximately 1,191,815 dengue cases between epidemiological week 1 and week 22 of 2019, including 546,589 laboratory-confirmed cases and 5,599 severe dengue cases.

The Western Pacific region also reported more than 375,000 suspected cases in 2019, including 176,411 cases in the Philippines and 100,028 in Malaysia. Rising disease prevalence is therefore expected to remain an important demand driver for dengue vaccines.

In May 2019, the U.S. FDA approved Dengvaxia for prevention of dengue caused by all dengue virus serotypes. The vaccine is a live attenuated tetravalent chimeric vaccine developed using recombinant DNA technology.

Dengue Vaccines Market Segmentation

Based on category, the market is segmented into live attenuated vaccines, chimeric live attenuated vaccines, and others. Live attenuated vaccines are expected to maintain a leading position, supported by increasing vaccination awareness, government funding, and the rising prevalence of infectious diseases.

By product, the market is divided into CYD-TDV (Dengvaxia) and others. CYD-TDV dominated the market in 2020, with the supplied data indicating approximately 76% effectiveness in preventing symptomatic, laboratory-confirmed dengue among individuals aged nine through 16 who had previously experienced laboratory-confirmed dengue disease.

Based on route of administration, the market is classified into subcutaneous and others, with the subcutaneous segment dominating in 2020. By end user, the market comprises hospitals, government institutes, specialty clinics, and others.

Regional Outlook

The global dengue vaccines market covers North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is expected to dominate revenue generation during the forecast period, supported by dengue prevalence and vaccine development opportunities across several endemic countries.

The market report provides revenue estimates for major regional markets and countries from 2021 to 2031, along with CAGR analysis for the same period.

Competitive Landscape

Major companies operating in the dengue vaccines market include Sanofi Pasteur Limited, Takeda Pharmaceutical Company Limited, Merck & Co. Inc., GlaxoSmithKline plc, GeneOne Life Science, Medigen Vaccine Biologics, Panacea Biotec Limited, Sun Pharmaceutical Industries Ltd., Serum Institute of India Pvt. Ltd., Biological E, and VabioTech.

These companies are focusing on R&D, clinical development, regulatory submissions, manufacturing expansion, strategic collaborations, and vaccine technologies designed to provide protection against multiple dengue serotypes.

Outlook

The dengue vaccines market is positioned for continued development as governments, pharmaceutical companies, and research institutions intensify efforts to address the global dengue burden. The projected 11% CAGR and market value of more than US$ 1.4 Bn by 2031 reflect growing investment in vaccine research, regulatory development, manufacturing capabilities, and immunization programs.

Future market progress will depend on the successful development of safe and effective vaccines offering broad protection against all four dengue serotypes, alongside improved affordability, production capacity, regulatory harmonization, and access in dengue-endemic countries.